Satoru Matsuda1, Hiroya Takeuchi2,3, Hirofumi Kawakubo1, Ryo Takemura4, Yusuke Maeda1, Yuki Hirata1,5, Takuji Kaburagi6, Tomohisa Egawa5, Tomohiko Nishi6, Masaharu Ogura7, Taku Miyasho8, Akihiko Okamura1, Shuhei Mayanagi1, Kazumasa Fukuda1, Rieko Nakamura1, Tomoyuki Irino1, Norihito Wada1, Yuko Kitagawa1. 1. Department of Surgery, Keio University School of Medicine, Tokyo, Japan. 2. Department of Surgery, Keio University School of Medicine, Tokyo, Japan. takeuchi@hama-med.ac.jp. 3. Department of Surgery, Hamamatsu University School of Medicine, Shizuoka, Japan. takeuchi@hama-med.ac.jp. 4. Biostatistics Unit, Clinical and Translational Research Center, Keio University Hospital, Tokyo, Japan. 5. Department of Surgery, Saiseikai Yokohamashi Tobu Hospital, Yokohama, Japan. 6. Department of Surgery, Keiyu Hospital, Yokohama, Japan. 7. Department of Surgery, Tokyo Dental College Ichikawa General Hospital, Ichikawa, Japan. 8. School of Veterinary Medicine, Rakuno Gakuen University, Ebetsu, Japan.
Abstract
PURPOSE: To arrange multidisciplinary treatment for esophageal cancer, a simple and accurate predictive marker for prognosis is required. The current multicenter prospective study aims to validate the prognostic significance of fibrinogen and albumin score (FA score) for esophageal cancer patients. PATIENTS AND METHODS: Patients who were planned to undergo surgical resection for esophageal cancer at four participating institutions were enrolled in this study. Patient background, clinicopathological factors, and blood concentration of plasma fibrinogen and albumin were collected. Patients with elevated fibrinogen and decreased albumin levels were allocated a score of 2; those with only one of these abnormalities were allocated a score of 1; and those with neither of these abnormalities were allocated a score of 0. Recurrence-free survival (RFS) and overall survival (OS) were evaluated as a primary endpoint. RESULTS: From four participating institutions, 133 patients were registered for the current analysis. The distribution of FA score of 0/1/2 was 84 (63%)/34 (26%)/15 (11%), respectively. In the analysis of primary endpoint, the preoperative FA score significantly classified RFS (FA score 1/2: HR 2.546, p = 0.013/6.989, p < 0.001) and OS (FA score 1/2: HR 2.756, p = 0.010/6.970, p < 0.001). We further evaluated the prognostic significance of FA score under stratification by pStage. As a result, with increasing FA score, RFS and OS were significantly worse in both pStage 0-I and II-IV groups. CONCLUSIONS: The prognostic impact of preoperative FA score was confirmed for esophageal cancer patients in the current multicenter prospective trial. FA score can be considered to predict postoperative survival and rearrange the treatment strategy before esophagectomy.
PURPOSE: To arrange multidisciplinary treatment for esophageal cancer, a simple and accurate predictive marker for prognosis is required. The current multicenter prospective study aims to validate the prognostic significance of fibrinogen and albumin score (FA score) for esophageal cancerpatients. PATIENTS AND METHODS: Patients who were planned to undergo surgical resection for esophageal cancer at four participating institutions were enrolled in this study. Patient background, clinicopathological factors, and blood concentration of plasma fibrinogen and albumin were collected. Patients with elevated fibrinogen and decreased albumin levels were allocated a score of 2; those with only one of these abnormalities were allocated a score of 1; and those with neither of these abnormalities were allocated a score of 0. Recurrence-free survival (RFS) and overall survival (OS) were evaluated as a primary endpoint. RESULTS: From four participating institutions, 133 patients were registered for the current analysis. The distribution of FA score of 0/1/2 was 84 (63%)/34 (26%)/15 (11%), respectively. In the analysis of primary endpoint, the preoperative FA score significantly classified RFS (FA score 1/2: HR 2.546, p = 0.013/6.989, p < 0.001) and OS (FA score 1/2: HR 2.756, p = 0.010/6.970, p < 0.001). We further evaluated the prognostic significance of FA score under stratification by pStage. As a result, with increasing FA score, RFS and OS were significantly worse in both pStage 0-I and II-IV groups. CONCLUSIONS: The prognostic impact of preoperative FA score was confirmed for esophageal cancerpatients in the current multicenter prospective trial. FA score can be considered to predict postoperative survival and rearrange the treatment strategy before esophagectomy.
Authors: Campbell S D Roxburgh; Jonathan M Salmond; Paul G Horgan; Karin A Oien; Donald C McMillan Journal: Ann Surg Date: 2009-05 Impact factor: 12.969
Authors: Bo Jan Noordman; Manon C W Spaander; Roelf Valkema; Bas P L Wijnhoven; Mark I van Berge Henegouwen; Joël Shapiro; Katharina Biermann; Ate van der Gaast; Richard van Hillegersberg; Maarten C C M Hulshof; Kausilia K Krishnadath; Sjoerd M Lagarde; Grard A P Nieuwenhuijzen; Liekele E Oostenbrug; Peter D Siersema; Erik J Schoon; Meindert N Sosef; Ewout W Steyerberg; J Jan B van Lanschot Journal: Lancet Oncol Date: 2018-06-01 Impact factor: 41.316